Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach

References

• TewariDJavaJJSalaniRLong-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group studyJ Clin Oncol201533131460146625800756
   PubMed Web of Science ®Google Scholar
• WrightAACroninAMilneDEUse and effectiveness of intra-peritoneal chemotherapy for treatment of ovarian cancerJ Clin Oncol201533262841284726240233
   PubMed Web of Science ®Google Scholar
• WalkerJLWenzelLHuangHA phase III trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and peritoneal carcinoma NCI-supplied agent(s): a GOG/NRG trial (GOG 252)Paper presented at: 47th Annual Meeting of the Society of Gynecologic OncologyMarch 19–22, 2016San Diego, CA
   Google Scholar
• WalkerJLArmstrongDKHuangHQIntraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group StudyGynecol Oncol20061001273216368440
   PubMed Web of Science ®Google Scholar
• WenzelLBHuangHQArmstrongDKHealth-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group StudyJ Clin Oncol200725443744317264340
   PubMed Web of Science ®Google Scholar
• PassotGVaudoyerDVilleneuveLWhat made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 proceduresJ Surg Oncol2016113779680327110915
   PubMed Web of Science ®Google Scholar
• SpiliotisJHalkiaELianosECytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III studyAnn Surg Oncol20152251570157525391263
   PubMed Web of Science ®Google Scholar
• BakrinNBerederJMDecullierEPeritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patientsEur J Surg Oncol201339121435144324209430
   PubMed Web of Science ®Google Scholar
• DeracoMKusamuraSVirzìSCytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trialGynecol Oncol2011122221522021665254
   PubMed Web of Science ®Google Scholar
• DeracoMVirzìSIuscoDRSecondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional studyBJOG2012119780080922571746
   PubMed Web of Science ®Google Scholar
• FagottiACostantiniBPetrilloMCytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two-year follow-upGynecol Oncol2012127350250523022234
   PubMed Web of Science ®Google Scholar
• ChanDLMorrisDLRaoAIntraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacyCancer Manag Res2012441342223226073
   PubMedGoogle Scholar
• HuoYRRichardsALiauwWHyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysisEur J Surg Oncol201541121578158926453145
   PubMed Web of Science ®Google Scholar
• HettingaJVKoningsAWKampingaHHReduction of cellular cisplatin resistance by hyperthermia: a reviewInt J Hypertherm1997135439457
   PubMed Web of Science ®Google Scholar
• ZuninoBRubio-PatiñoCVillaEHyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90Oncogene201635226126825867070
   PubMed Web of Science ®Google Scholar
• PelzJOVetterleinMGrimmigTHyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermiaAnn Surg Oncol20132041105111323456378
   PubMed Web of Science ®Google Scholar
• McConnellYJMackLAFrancisWPHIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancyJ Surg Oncol2013107659159623129533
   PubMed Web of Science ®Google Scholar
• HelmCWHyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?J Gynecol Oncol20152611225609161
   PubMed Web of Science ®Google Scholar
• BatistaTPComment on: surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III studyAnn Surg Oncol Epub2017111
   Web of Science ®Google Scholar
• HerzogTJThe role of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer: hope or hoax?Ann Surg Oncol201219133998400022833000
   PubMed Web of Science ®Google Scholar
• HarterPReussASehouliJBrief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et alInt J Gynecol Cancer201727224624728114231
   PubMed Web of Science ®Google Scholar
• ChivaLMGonzalez-MartinAA critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancerGynecol Oncol2015136113013525434634
   PubMed Web of Science ®Google Scholar
• MarkmanMHyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: a critical need for an evidence-based evaluationGynecol Oncol200911314519176238
   PubMed Web of Science ®Google Scholar
• VergoteITropéCGAmantFNeoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancerN Engl J Med20103631094395320818904
   PubMed Web of Science ®Google Scholar
• KehoeSHookJNankivellMPrimary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialLancet2015386999024925726002111
   PubMed Web of Science ®Google Scholar
• D’HondtVGoffinFRocaLInterval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in first-line treatment for advanced ovarian carcinoma: a feasibility studyInt J Gynecol Cancer201626591291727051055
   PubMed Web of Science ®Google Scholar
• FerrandinaGSallustioGFagottiARole of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trialBr J Cancer200910171066107319738608
   PubMed Web of Science ®Google Scholar
• KangSKimTJNamBHPreoperative serum ca-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysisJ Surg Oncol20101011131720025071
   PubMed Web of Science ®Google Scholar
• FagottiAFerrandinaGFanfaniFProspective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinomaAm J Obstet Gynecol20081996642.e1642.e618801470
   PubMed Web of Science ®Google Scholar
• SugarbakerPHPeritonectomy proceduresAnn Surg1995221129427826158
   PubMed Web of Science ®Google Scholar
• WrightAABohlkeKArmstrongDKNeoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice GuidelineJ Clin Oncol201634283460347327502591
   PubMed Web of Science ®Google Scholar
• OndaTSatohTSaitoTComparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602Eur J Cancer201664223127323348
   PubMed Web of Science ®Google Scholar
• FagottiAFerrandinaGVizzielliGPhase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of perioperative outcomeEur J Cancer201659223326998845
   PubMed Web of Science ®Google Scholar
• TsubamotoHItaniYItoKPhase II study of interval debulking surgery followed by intraperitoneal chemotherapy for advanced ovarian cancer: a Kansai Clinical Oncology Group study (KCOG9812)Gynecol Oncol20131281222723063999
   PubMed Web of Science ®Google Scholar
• MackayHGallagherCJParulekarWROV21/PETROC: a randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC)J Clin Oncol20163418 Suppl Abstr LBA5503
   Web of Science ®Google Scholar
• da CostaAAValadaresCVBaiocchiGNeoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancerAnn Surg Oncol201522Suppl 3S971S97826014155
   PubMed Web of Science ®Google Scholar
• ColomboPELabakiMFabbroMImpact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancerGynecol Oncol2014135222323025220627
   PubMed Web of Science ®Google Scholar
• GouySFerronGGlehenOResults of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancerGynecol Oncol2016142223724227246305
   PubMed Web of Science ®Google Scholar
• Van DrielWSikorskaKvan LeeuwenJSA phase 3 trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancerPaper presented at: 53rd ASCO Annual MeetingJune 2–6, 2017Chicago, IL
   Google Scholar
• LimMCSuk-JoonCYooHJRandomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancerPoster session presented at: 53rd ASCO Annual MeetingJune 2–6, 2017Chicago, IL
   Google Scholar
• OeiALVriendLEKrawczykPMTargeting therapy-resistant cancer stem cells by hyperthermiaInt J Hyperthermia2017112
   Web of Science ®Google Scholar
• KusamuraSEliasDBarattiDDrugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapyJ Surg Oncol200898424725218726886
   PubMed Web of Science ®Google Scholar
• Di GiorgioADe IacoPDe SimoneMCytoreduction (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 casesAnn Surg Oncol201724491492227896512
   PubMed Web of Science ®Google Scholar
• EliasDRaynardBBonnayMHeated intraoperative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studiesEur J Surg Oncol200632660761316621432
   PubMed Web of Science ®Google Scholar
• GlehenOCotteEKusamuraSHyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusionJ Surg Oncol200898424224618726885
   PubMed Web of Science ®Google Scholar
• HorowitzNSMillerARungruangBDoes aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182J Clin Oncol201533893794325667285
   PubMed Web of Science ®Google Scholar
• MartinezANgoCLeblancESurgical complexity impact on survival after complete cytoreductive surgery for advanced ovarian cancerAnn Surg Oncol20162382515252127008588
   PubMed Web of Science ®Google Scholar
• ChuaTCYanTDSaxenaAShould the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortalityAnn Surg2009249690090719474692
   PubMed Web of Science ®Google Scholar